Breaking the Cycle of Poorly Executed Site Initiation Visits
Trial leaders recognize traditional site initiation processes often lead to excessive delays but have struggled to adapt and improve.
They know that delays in study startup mean patients must wait even longer to access critical treatments. They also know that delays in activating sites can add between $600,000 to $8 million
